Telomir announces Telomir-1 reverses calcium dysregulation in human cell lines

Telomir Pharmaceuticals, Inc.

Telomir-1 fully reversed calcium dysregulation in human keratinocyte (HaCaT) and retinal (ARPE-19) cell lines under oxidative stress.
Treatment also reduced oxidative stress, preserved cellular integrity, and prevented cell death; untreated cells showed degeneration.
Telomir is advancing preclinical studies toward human trials for neurodegenerative, retinal, and metabolic diseases.
The study was conducted in multiple human cell lines, supporting Telomir-1 as a potential first-in-class therapy for aging-related conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.